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Experimental study 
The effects of procainamide, mexiletine, and amiodarone on automaticity, conduc- 
tion, and refractoriness were studied in a model of heterotopic heart transplantation 
in dogs that combined an innervated heart (recipient) and a denervated trans- 
planted heart (donor). After the surgical procedure, 500 mg procainamide (n = 13), 
200 mg plus 0.1 mg/kg per minute mexiletine (n = 10), or 150 mg amiodarone (n = 
10) was administered intravenously. During a baseline period and after drug 
administration, each heart was assessed for atrioventricular interval; cycle length; 
sinoatrial conduction time; atrioventricular node anterograde and retrograde block 
points; atrioventricular node and ventricular antegrade etfective refractory periods; 
PR, QRS, and QT intervals on electrocardiogram; systemic arterial, pulmonary 
arterial, central venous, and pulmonary capillary wedge pressures; and cardiac 
output. In recipients, procainamide r duced cardiac output, depressed sinus auto- 
maticity, slowed conduction time without affecting the QRS interval, nd prolonged 
the nodal and ventricular refractoriness; in donor hearts, it depressed automaticity 
and prolonged nodal refractoriness, but did not modify conduction or ventricular 
refractoriness. Mexiletine only moderately depressed sinus automaticity in recipient 
hearts; it did not affect the other parameters either in recipient or transplanted 
hearts, nor did it alter the hemodynamic situation. Amiodarone produced hypoten- 
sion, reduced cardiac output, and prolonged all the electrophysiologic intervals 
except the QRS interval in recipient hearts. These changes were even more 
pronounced in the transplanted hearts and led to extreme sinus bradycardia n four 
cases. Of these three drugs, mexiletine appears to be the safest should treatment for 
arrhythmias be necessary in transplant recipients. (J THORAC CARDIOVASC SURG 
1995;109:899-904) 
L. Alvarez, PhD, FCCP, a C. Escudero, PhD, a A. Torralba, PhD, b and I. Millän, MS, c 
Madrid, Spain 
A ccelerated coronary artery disease is a complica- tion that occurs systematically after heart trans- 
plantation, constituting the third most frequent 
cause of death. At Stanford, it has been reported to 
be the determinant of 60% of retransplantation 
procedures. 1 The patients do not normally report 
angina because the heart is denervated, and the first 
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signs of the development of this complication are 
usually life-threatening ventricular arrhythmias, 
congestive heart failure as a result of myocardial 
ischemia, silent myocardial infarction, and sudden 
death. 
There is not a great deal of information concern- 
ing the response of the transplanted heart to differ- 
ent drugs 2' 3 or, more specifically, to antiarrhythmic 
agents. The purpose of this report was to compare 
the action of procainamide (class LA), mexiletine 
(class Iß), and amiodarone (class III) on the con- 
duction system of transplanted hearts with the ef- 
fects of these agents on normal hearts, with use of a 
model of heterotopic transplantation i  dogs. 
These drugs were selected because procainamide 
and amiodarone are administered intravenously 
with certain frequency, the former to assess the 
899 
9 0 0 Alvarez et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
May 1995 
response of an arrhythmia to long-term oral treat- 
ment and the latter for short-term control of certain 
severe ventricular arrhythmias. 4 Although amioda- 
rone is classified as a class I I I  agent among the 
antiarrhythmic drugs, s it also exhibits class Iß  ac- 
tion6; thus it was considered appropriate to include 
mexiletine in the study. 
Material and methods 
Heart transplantation was done in healthy, adult mon- 
grel dogs that weighed between 20 and 25 kg; the weights 
of the donor dogs ranged from 15 to 20 kg. Care of the 
animals complied with the rules stipulated by the "Prin- 
ciples of Laboratory Animal Care" and the «Guide for the 
Care and Use of Laboratory Animals" issued by the 
National Society for Medical Research and the National 
Academy of Sciences, respectively. 
The animals were divided into three groups according 
to the drug they received: procainamide (n = 13), 500 mg 
bolus over 5 minutes, resulting in a dosage range of 20 to 
25 mg/kg body weight; mexiletine (n = 10), 200 mg bolus 
over 5 minutes, followed by continuous infusion of 0.1 
mg/kg per minute; or amiodarone (n = 11), 150 mg bolus 
over 2 minutes, resulting in a dosage range of 7 to 7.5 
mg/kg body weight. 
Anesthesia was induced with thiopental (20 mg/kg body 
weight). After endotracheal intubation, the dogs were 
connected to an Ohmeda 7000 ventilator (Ohmeda, BOC, 
Madison, Wis.) and the lungs ventilated at a tidal volume 
of 15 to 20 tal/kg body weight. Maintenance of anesthesia 
was aehieved with diazepam (a single 5 mg dose after 
intubation), fentanyl (5 to 10/xg/kg body weight), pancu- 
ronium bromide (2 mg after intubation and 1 mg/hour), 
and 30% oxygen and nitrous oxide. No additional drugs 
were administered in the 90 minutes before the electro- 
physiologic studies were done; thus, once thoracotomy 
was concluded, anesthesia was maintained exclusively with 
oxygen and nitrous oxide. Oxygenation and aeid-base 
status were monitored both in transplanted and recipient 
hearts throughout he trial, as were systemic arterial 
pressure and surface electrocardiogram. 
In the recipients, in addition to electrocardiogram nd 
determination of arterial pressure, central venous pres- 
sure, pulmonary arterial pressure, pulmonary capillary 
wedge pressure, and cardiac output were measured uring 
a baseline period, after transplantation, and between 5 
and 15 minutes after infusion of the antiarrhythmic agent 
by introdueing a 7F Swan-Ganz catheter (Baxter Health- 
care Corp., Edwards Div., Santa Ana, Calif.) into the right 
external jugular vein. Central venous pressure was main- 
tained constant hroughout the procedure by means of 
fluid infusion. 
The surgical technique used for transplantation was 
that described by Barbero-Marcial and associates, 7 in 
which the left chambers of the two hearts are connected in
parallel, without extracorporeal circulation. To this end, 
the left atria and the aortas of donor and recipient were 
anastomosed. Because in this transplant model the right 
cavities of the donor were deprived of systemic onnec- 
tion, the pulmonary artery was anastomosed to the left 
atrial appendage to create a passageway into the blood- 
stream of the coronary sinus: although this established a 
right-to-left shunt, it had no hemodynamic or oxymetric 
impact. 
The transplanted heart was subjected to a period of 
ischemia of approximately 45 to 50 minutes. Satisfactory 
recovery of the heartbeat occurred spontaneously or was 
achieved by means of electric shock, and sinus rhythm was 
reestablished immediately in all cases. 
Once the hemodynamic situation stabilized and normo- 
thermia was achieved in the transplanted myocardium, 
flxed pentapolar reference lectrodes were sutured into 
the epicardium of the right chambers of the two hearts. 
The electrodes were connected to a computer-assisted 
system based on microprocessors that was capable of 
integrating the signals, listing the results on a display, 
printing them, and plotting them on previously designed 
maps. 8
The signals thus obtained were filtered between 50 and 
500 Hz. With these signals, and by means of the system's 
internal stimulator, 9 programmed stimulation of the two 
hearts was achieved (5 V of amplitude and 1 msec of pulse 
width). The electrogram printout was obtained by inter- 
connecting the system to an HTR-8 polygraph (PPG 
Hellige GmbH, Freiburg, Germany). 
The electrophysiologic study included the following 
determinations. 
Cycle length. The cycle length (CL) measures the in- 
terval of time between two spontaneous cardiac ycles and 
thus is the inverse of the heart rate, as expressed by the 
equation CL = 6 × 104. heart rate -1. It is used to assess 
sinus node automaticity. 
Sinoatrial conduction time. The sinoatrial conduction 
time (SACT) reflects the capacity of transmission of an 
impulse originating in the sinus node to the perisinus area. 
This was determined by the method described by Narula 
and associates, 1°which consists of atrial stimulation by a 
train of eight stimuli at a rate slightly higher than the 
spontaneous rate. The SACT is the difference between the 
first poststimulation cycle and the basic spontaneous cycle, 
divided by 2. 
Antegrade block point and retrograde block point. The 
antegrade block point (ABP) and retrograde block point 
of the atrioventricular node were defined as the longest 
(atrial or ventricular) CL at which Wenckebach periodic- 
ity occurred during incremental (atrial or ventricular) 
pacing. They were calculated by stimulation of atrium and 
ventride, respectively, atCLs that decreased progressively 
by 50 msec. These parameters assess the capacity of the 
atrioventricular hode to conduct stimuli antegradely and 
retrogradely and thus a rea  measure, although indirect 
and somewhat imprecise, of the nodal refractoriness. 
Effective refractory periods. The antegrade ffective 
refractory period of the atrioventricular node (ARPAVN) 
and the ventricular effective refractory period (VRP) were 
defined as the longest interval of time between two 
stimuli, the basic stimulus and the extrastimulus, in which 
the latter did not achieve a propagated response. They 
were calculated by stimulation, atrial and ventricular, 
respectively, at a fixed cycle and introduction of an 
extrastimulus with progressive reduction by 8 msec of the 
coupling interval. These parameters are used to assess the 
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Table I. Hemodynamic study 
sAP d/IP C VP s PA dPA WP CO 
Basal 162.5 _+ 27.5 92.1 ± 17.9 2.1 _+ 1.2 14 _+ 3.4 8.2 _+ 2.5 4.7 _+ 2.1 3.8 -_ 1.2 
Tx 149 _+ 27 87.7 + 16.4 3.8 _+ 1.9 14.4 _+ 3.9 12.3 _+ 5.5 10 -+ 2.4 3.3 + 0.9 
After P 154.2 _+ 30.1 92.4 2 15 3.6 _+ 2.1 16.3 +- 3.8 12.7 -+ 1.9 8.8 + 1.6 3 _+ 1" 
Basal 177.1 _+ 24.8 113.6 + 12.2 4.6 + 2.6 21.1 + 4.9 14 _+ 4 10.6 _+ 4.4 5.8 _+ 2.1 
Tx 171.5 + 22.3 101.9 + 15.7 4.1 _+ 2 21.1 _+ 7.1 15.7 -+ 5.4 8.6 -+ 3.2 5.5 _+ 2.1 
After M 165.5 _+ 22 102.5 -+ 13 4.2 _+ 1.8 22 -+ 8.5 15.6 -- 3.7 7.9 + 3 4.7 _+ 2 
Basal 168.1 _+ 22.9 99 -+ 25.8 4.1 _+ 1.6 15.8 -- 2.3 9.9 -+ 2.8 6.3 -+ 3.2 3.4 _+ 1.6 
Tx 151.7 _+ 28.4 90.1 + 18.5 3.7 + 2.1 17.2 -+ 6.7 9.7 _+ 5.6 6.1 _+ 2.4 2.4 _+ 1 
After A 86.9 _+ 32.6* 49.3 + 18" 2.1 _+ 1.2t 16.4 _+ 4.4 8.3 _+ 5.4 4.2 -- 2.3 1.6 _+ 0.5~ 
sAP, Systolic arterial pressure; dAP, diastolic arterial pressure; CVP, central venous pressure; sPA, systolic pulmonary arterial pressure; dPA, diastolic 
pulmonary arterial pressure; WP, wedge pressure; CO, cardiac output; Tx, posttransplant; P, procainarnide; M, mexiletine; A, amiodarone. 
*p < 0.01. 
~'p = 0.02 (versus baseline and posttransplant periods). 
capacity of the atrioventricular node and of the ventricle 
to propagate extrasystole. 
Atrioventricular interval. The atrioventricular interval 
(AV interval) is determined by addition of the AH and 
HV intervals, which represent the intranodal conduction 
time and the His-Purkinje conduction time (specific for 
ventricular conduction), respectively. 
The aforementioned electrophysiologic parameters 
were determined both in recipient and grafted hearts after 
transplantation a d between 5 and 15 minutes after 
infusion of the antiarrhythmic drug. 
The surface electrocardiogram, which logically per- 
tained exclusively to the recipient heart, measured the PR 
interval (which includes the intraatrial, atrioventricular 
node, and His-Purkinje conduction times), the QRS com- 
plex (duration of intraventricular conduction), and the QT 
interval (which reflects the duration of ventricular depo- 
larization and repolarization a d approximates the action 
potential duration). These intervals were measured after 
transplantation a d between 5 and 15 minutes after 
infusion of the antiarrhythmic drug. 
The results have been expressed as the mean plus or 
minus the standard eviation. For the statistical analysis, 
the Mann-Whitney U test was used to compare the 
differences between the means of two distributions (trans- 
planted versus recipient heart) and Wilcoxon's t test was 
applied to paired data (baseline period versus postadmin- 
istration levels in each heart). Ap value of less than 0.05 
was considered to indicate significance. 
Results 
Procainamide. Injection of this drug produced a
decrease in the cardiac output as compared with 
that during baseline and posttransplantation periods 
(p < 0.01) without modifying systemic, pulmonary, 
or wedge pressures (Table I). 
With respect o the electrophysiologic study (Ta- 
ble Il), in the recipient heart, different degrees of 
prolongation were detected in all the parameters 
studied: CL (p < 0.01), SACT (p < 0.02), ABP (p < 
0.01), ARPAVN (p < 0.05), VRP (p < 0.01), and 
AV interval (p < 0.02). In the surface lectrocardio- 
gram (Table III), the PR and QT intervals were 
prolonged (p < 0.05 and p < 0.02, respectively), 
whereas the QRS complex underwent no significant 
changes. 
In the transplanted hearts, CL (p < 0.01), SACT 
(p < 0.05), and ARPAVN (p < 0.01) were pro- 
longed. ABP, VRP, and, to a lesser degree, the AV 
interval were also longer, but these changes were 
not statistically significant (Table II). 
Mexiletine. This drug produced no substantial 
modifications in the hemodynamic situation (Table 
I). 
In the electrophysiologic aspect, its only effect was 
the moderate prolongation of the recipient heart CL 
(p < 0.05). The drug did not significantly change the 
atrioventricular node conduction in ARPAVN and 
VRP either in recipient or transplanted hearts (Ta- 
bles II and III). In the transplanted hearts, the only 
significant change was the prolongation of the 
SACT, although this parameter emained at all 
times within the normal range and did not differ 
significantly with respect o findings in the recipient 
hearts. 
Amiodarone. This drug produced a significant 
decrease, with respect o the baseline and posttrans- 
plantation hemodynamic situations (Table I), in the 
systemic arterial pressure, both diastolic and systolic 
(p < 0.01 in both cases); in the central venous 
pressure (p = 0.02) despite fluid infusion in the 
attempt o maintain this value constant; and in 
cardiac output (p = 0.02). 
In the recipient heart (Table II), amiodarone 
significantly prolonged CL, ABP, ARPAVN, and 
VRP (p < 0.01 in every case), whereas SACT and 
AV interval were unchanged. The surface electro- 
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Table II. Electrophysiologic study 
CL SA CT ABP ARPA VN VRP A V interval 
Procainamide 
Recipient 
Basal 346.1 +_ 52.8 39.2 _+ 10.5 169.2 _+ 32.5 127.7 _+ 32.1 144.1 _+ 16.7 98.4 _+ 16.2 
Post 426.1 _+ 61.3 49.2 _+ 12.5 203 + 37 152.3 _+ 30.3 174.1 -+ 26.7 107.7 _+ 16.4 
p Value <0.01 <0.02 <0.01 <0.05 <0.01 <0.02 
Donor 
Basal 472.3 _+ 58.7 34.5 _+ 10.7 220 + 53.7 159.1 _+ 34.7 178.8 -+ 20.2 93 + 9.4 
Post 560 + 66.8 43.3 _+ 9.8 237.5 _+ 43.3 193.3 + 35.7 200 -+ 20.6 97.7 _+ 14.2 
p Value <0.01 <0.05 NS <0.01 NS NS 
Mexiletine 
Recipient 
Basal 355.4 _+ 71.1 44.5 _+ 8.2 181.8 _+ 40.4 133.6 + 21.1 149 -+ 22.5 108.1 _+ 14 
Post 385.4 _+ 90.3 50.9 _+ 11.3 186.3 _+ 39.3 135 _+ 16.5 149 -+ 23.3 112.7 _+ 14.9 
p Value <0.05 NS NS NS NS NS 
Donor 
Basal 480 + 62.7 33.6 _+ 6.7 213.6 _+ 55.1 146.3 _+ 34.4 185.4 -+ 21.1 104.5 _+ 18.6 
Post 489.1 _+ 82.1 43.6 _+ 9.2 213.6 _+ 32.3 150.9 _+ 41.1 182.7 + 17.9 110.9 _+ 13.7 
p Value NS <0.01 NS NS NS NS 
Amiodarone 
Recipient 
Basal 349.1 _+ 41.1 44.5 _+ 12.1 168.1 _+ 25.2 130.9 _+ 18.6 155.4 + 28.7 90.9 _+ 10.4 
Post 441.8 _+ 48.5 45.4 _+ 10.3 231.8 + 25.2 150.9 -+ 20.2 180.9 -+ 23.8 92.7 + 11.9 
p Value <0.01 NS <0.01 <0.01 <0.01 NS 
Donor 
Basal 496.3 _+ 65.7 39.1 + 9.4 227.2 _+ 34.3 165.4 _+ 24.2 208.1 _+ 47.1 110 + 20.5 
Post 616 _+ 122.7 47 _+ 13.3 377.2 + 78.6 268.9 -+ 104.5 247 -+ 60.2 130 _+ 27.1 
p Vaiue <0.01 NS <0.01 <0.01 <0.01 <0.05 
Post, After drug administration; NS, not significant. 
Table III. Electrocardiographic study 
PR QRS QT 
Procainamide 
Basal 99.2 _+ 13.2 56.9 _+ 11 206.9 + 26.5 
Post 106.1 _+ 14.4 60 _+ 11.5 224.6 _+ 29 
p Value <0.05 NS <0.02 
Mexiletine 
Basal 106.3 + 9.2 54.5 _+ 9.3 211.8 _+ 30.9 
Post 111.8 _+ 11.6 56.3 _+ 8.1 213.6 _+ 33.8 
p Value NS NS NS 
Amiodarone 
Basal 93.6 _+ 10.2 54.1 _+ 5.8 227.2 _+ 22.4 
Post 102.7 _+ 9 57.7 _+ 9.3 263.6 _+ 32.6 
p Value <0.05 NS <0.01 
Post, After drug administration; NS, not significant. 
cardiogram (Table III) disclosed the prolongation of
the PR and QT intervals (p < 0.05 and p < 0.01, 
respectively), whereas no significant modifications 
were detected in the QRS complex. 
The effects of amiodarone on the transplanted 
heart (Table II) were similar to those observed in the 
recipient hearts, although the prolongations of CL, 
ABP, ARPAVN, and VRP were more marked. With 
regard to automaticity, the only noteworthy event was 
extreme sinus bradycardia, which was produced in four 
cases and led to a rhythm of ventricular escape. In 
contrast to the findings in the recipient heart, the AV 
interval was also significantly onger (p < 0.05). 
Diseussion 
From the clinical point of view, arrhythmias are 
probably generated as a consequence of the inter- 
action of several anatomic and functional factors. 11 
Thus it is important o determine the direct and 
indirect effects involved in the mechanism of action 
of each antiarrhythmic drug. The result will depend 
on the interrelationship between these two types of 
actions and the individual situation of each patient. 
We consider the experimental model used in this 
study 12 to be suitable because it enabled us to 
compare the effects of a given drug on two hearts 
with different degrees of innervation that shared the 
same circulatory system in such a way that the serum 
concentrations of the drug and other metabolic 
products were identical. Thus the possible differ- 
ences between recipients and donors could not be 
attributed to these levels. 
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In the early postoperative p riod, it is unusual for 
transplant recipients to have significant arrhythmias 
that necessitate intravenous antiarrhythmic therapy, 
and the effects of long-term oral administration 
of some antiarrhythmic drugs could differ from 
those associated with the acute intravenous setting. 
Nevertheless, we have considered that, even un- 
der the experimental conditions used here, the 
response of the conduction system of normal and 
denervated hearts to antiarrhythmics could bear 
certain relevance to the knowledge of the mechanisms 
of action of these drugs and to their use in transplant 
recipients. 
Procainamide. Aside from the electrophysiologic 
effects associated with the class lA antiarrhythmics, 
the drugs in this group show peripheral and cardiac 
anticholinergic action, direct relaxing effects on 
smooth muscle, and a-adrenergic blocking. The net 
result depends on the strength of each specific agent 
in each of these aspects and the vagal tone of the 
individual patient o whom the drugs are adminis- 
tered.», 13 
Procainamide xhibits weak anticholinergic and 
a-adrenergic blocking action. Because the sympa- 
thetic division of the autonomic nervous system 
predominates in the dog, 12 it could be expected that 
these effects of the drug would have little impact on 
the heart recipients in our study. 
The reduction in cardiac output produced after 
injection of procainamide might be attributed to the 
negative inotropism of this drug, which is more 
evident when administered intravenously, 13'14 al_ 
though the decrease in the heart rate may have 
played some role. The intravenous administration.of 
procainamide is also reportedly associated with de- 
creases in the systemic arterial pressure secondary 
to peripheral vasodilation resulting from a-adrener- 
gic blockadeJ 3' 1» As could be expected, under the 
experimental conditions established in this study, 
the drug did not substantially modify the peripheral 
vascular esistances. 
From the electrophysiologic point of view, pro- 
cainamide behaved in general as previously de- 
scribed,4, 13-19 depressing sinus automaticity, slowing 
conduction, and prolonging the refractoriness both 
in recipient and transplanted hearts, although in the 
latter the ABP, VRP, and AV interval were not 
significantly longer. There was no sign of facilitation 
of conduction caused by a vagolytic effect, 13 perhaps 
for the reasons suggested previously, although a 
possible role for the prolongation of the QRS 
complex cannot be ruled out. 
Mexiletine. Mexiletine has limited hemodynamic 
and electrophysiologic effects 4' 13,14, 20, 21 except when 
used in high doses or with rapid intravenous ad- 
ministration: in these circumstances the drug can 
produce hypotension, bradycardia, and conduction 
slowing. 2° In our study, it had no impact aside from 
a moderate depression of the sinus automaticity 
in the recipient hearts. We can offer no explanation 
for the prolongation of the SACT observed in the 
transplanted hearts, although the reduced value of 
this parameter in the baseline situation might sug- 
gest the existence of an entry blocker that normal- 
ized after administration of the drug. 
Amiodarone. Amiodarone has a /3-adrenergic 
blocking effect, and thus a myocardial depressant 
effect, although it can be counteracted by the a- 
adrenergic action it also possesses, reducing the pe- 
ripheral vascular esistances by vasodilation. 6' 13, 14, 20, 22 
It has been reported that the myocardial depression 
lacks relevance in human subjects who receive long- 
term oral or intravenous amiodarone treatment at low 
doses,6, 22 but the antiadrenergic a tion appears to be 
more relevant during intravenous administration and 
in dogs. In these animals, in addition to significantly 
decreasing the systemic arterial pressure, amiodarone 
also reduces cardiac output, 22 a description that coin- 
cides exactly with the findings in our study. 
In the electrophysiologic aspect, amiodarone pro- 
duced the expected effects in both recipient and trans- 
planted hearts, with the effects being more marked in 
the latter: depression of the sinus automatici- 
ty6, 14, 16, 23 prolongation of the ARPAVN and VRP,* 
and prolongation of repolarization 16'17, 24, 25 as sig- 
naled by the increase in the QT interval. 4' 6, 14, 17, 22-24 
Different reports disagree with respect to conduc- 
tion slowing, a fact that may sometimes be attrib- 
uted to the route of administration of the drug. 6' 22 
In the recipients in our study, neither the AV 
interval nor the intraventricular conduction (QRS 
complex) were prolonged. 2°' 2» There was, however, 
a moderate lengthening of the PR interval. 14' 2o In 
contrast, in the donors, the AV interval was pro- 
longed, a finding that would agree with the existence 
of a direct depressor effect of amiodarone on the 
atrioventricular nodal conduction of the impulse. 2°' 2» 
According to the results obtained in this study, it 
can be expected that the intravenous administration 
of procainamide toheart ransplant recipients might 
produce a depression of the sinus automaticity equiv- 
alent to that observed in innervated hearts, but a less 
* References 4, 6, 13, 14, 16, 17, and 23 through 25. 
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marked effect on the conduction and refractoriness. In 
contrast, intravenous amiodarone administration may 
depress the automaticity, refractoriness, and conduc- 
tion more severely in the transplant recipient. Thus its 
administration to this patient population, when indi- 
cated, should be done under strict control. Mexiletine 
did not modify the electrophysiologic parameters an- 
alyzed in the transplanted hearts. Therefore its use 
would be safe in the treatment of arrhythmias gener- 
ated in this type of patient. 
We thank M. Messman for her translation and editorial 
help. 
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